The Rapidly Evolving Landscape of First‐Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review

BACKGROUND: Metastatic urothelial carcinoma (mUC) historically is treated with first‐line platinum‐based combination chemotherapy, preferably cisplatin plus gemcitabine whenever possible. In recent years, multiple classes of targeted therapy have demonstrated benefit, with some receiving approval in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lavoie, Jean‐Michel, Sridhar, Srikala S., Ong, Michael, North, Scott, Alimohamed, Nimira, McLeod, Deanna, Eigl, Bernhard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Genitourinary Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342568/
https://www.ncbi.nlm.nih.gov/pubmed/34028134
http://dx.doi.org/10.1002/onco.13827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342568/
https://www.ncbi.nlm.nih.gov/pubmed/34028134
http://dx.doi.org/10.1002/onco.13827

Ejemplares similares